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Abstract: Introduction: Cardiorenal syndrome (CRS) is a disorder of the heart and kidney whereby interactions between 
the 2 organs can occur. We recorded the clinical features of CRS in patients consecutively admitted to an Internal   
Medicine ward. 
Patients and Methods: We retrospectively analyzed the anthropometric, history, clinical, biochemical and treatment   
characteristics in 438 out of 2,998 subjects (14.6%) admitted to our unit (from June 2007 to December 2009), diagnosed 
with CRS, according to Acute Dialysis Quality Initiative (ADQI) recommendations. Estimated glomerular filtration 
(eGFR) was calculated using several equations: MDRD (Modification of Diet in Renal Disease; 2 variations GFRMDRD186, 
GFRMDRD175), Mayo, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Cockroft-Gault. 
Results: Mean age was 80±8 years, 222 (50.6%) were males, 321 (73.2%) were smokers, 229 (52.2%) were diabetic, 207 
(47.2%) had a history of acute myocardial infarction, 167 (38.1%) had angina, 135 (30.8%) were affected by cerebro- 
vascular disease, 339 (77.3%) had peripheral arterial disease. CRS was type 1 in 211 cases (48.2%), type 2 in 96 (21.9%), 
type 3 in 88 (20.1%), type 4 in 29 (6.6%) and type 5 in 14 (3.2%). eGFR, calculated by different formulae, ranged  
between 31 and 36 ml/min/1.73 m
2. GFR was lower in CRS type 3 than in the other types, and the values ranged between 
24 and 27 ml/min/1.73 m
2. Mean hospital length-of-stay (LOS) was 9.8±6.3 days. Diuretics were the most prescribed 
medication (78.7%); only 5 patients underwent haemodialysis. 
Conclusions: CRS is common, especially in the elderly. CRS Type 1 was the prevalent subset and patients had stage 3-4 
renal insufficiency. Results obtained from the GFR equations were similar although the Mayo equation tended to overes-
timate the eGFR. 
Keywords: Cardio-renal syndrome, heart failure, chronic kidney disease, renal function, heart disease.  
INTRODUCTION 
  Interactions between kidney and heart have recently been 
defined and classified by the consensus conference of the 
Acute Dialysis Quality Initiative (ADQI) [1]. The clinical 
relevance of cardio-renal syndrome (CRS) is still a matter of 
debate, and the time course of kidney-heart interaction is not 
clear. This is probably because the physiological, biochemi-
cal and hormonal relationships between the heart and the 
kidney are complex [2]. It follows, that the management of 
patients with CRS could sometimes be unsuitable.  
  Understanding the pathophysiology of CRS might   
suggest therapies that can interrupt dangerous feedback 
loops. However, information regarding the clinical features 
of different types of CRS in Internal Medicine settings is   
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very limited. Thus, we identified patients with CRS admitted 
to an Internal Medicine ward, in order to characterize the 
disorder and assess its impact in clinical practice. 
PATIENTS AND METHODS 
 This  retrospective study was performed under the terms 
of the Declaration of Helsinki. 
  Adult Caucasian patients (n = 438), selected from 2998 
subjects consecutively discharged from our 30-bed medical 
ward from June 2007 to December  2009 with CRS, were 
evaluated. The reason for hospitalization was cardiovascular 
disorder in 26%, pulmonary disorder in 30%, digestive dis-
order in 20% and other disorders (including urogenital, 
metabolic, neurologic, osteoarticular) in 24%. CRS was di-
agnosed according to the ADQI criteria [1], and patients 
were thereafter classified according to the 5 types (see be-
low). Congestive heart failure (CHF) was diagnosed accord-
ing to the European Society of Cardiology criteria [3]. 
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and chest pain, peripheral arterial disease (PAD), cere-
brovascular disease and hospital length-of-stay (LOS) were 
also recorded. 
  IHD, cardiovascular disease (CVD) and PAD were ascer-
tained based on history and/or presence of any combination 
of specific signs, previous diagnosis or treatment. For each 
patient, renal function was evaluated by estimated glomerular 
filtration rate (eGFR) using the following equations (SCr = 
serum creatinine): 
  Modification of Diet in Renal Disease (MDRD)186 for-
mula [4]: GFRMDRD186 = 186 x (SCr)
–1.154 x [age(years)
–0.203 x 
(0.742 if female) x (1.212 if African-American) 
 MDRD175 formula [5]: GFRMDRD175 = 175 x (SCr)
–1.154 x 
[age (years)
–0.203 x (0.742 if female) x (1.212 if African-
American) 
  Mayo Clinic Quadratic formula [6]: GFRMAYO = 
exp[1.911 + 5.249/SCr – 2.114/SCr
2 – 0.00686 x age (years) 
– 0.205 (if female)] 
  Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) formula [7]: 
  – If female and if SCr  0.7 mg/dl: 
 GFRCDK-EPI = 144 x SCr/0.7
–0.329 x 0.993
age 
  – If female and if SCr > 0.7 mg/dl: 
 GFRCDK-EPI = 144 x SCr/0.7
–1.209 x 0.993
age 
  – If male and if SCr  0.9 mg/dl: 
 GFRCDK-EPI = 141 x SCr/0.9
–0.411 x 0.993
age 
  – If male and if SCr > 0.9 mg/dl: 
  GFR CDK-EPI = 141 x SCr/0.9
–1.209 x 0.993
age 
  Cockcroft-Gault formula [8]:  
 GFRC-G = [140-age(years)] x body weight (Kg) / 72 x SCr 
(mg/dl) ( x 0.85 if female) 
  Acute renal failure was defined as a 0.5 mg/dl increase in 
SCr if the baseline serum creatinine was 1.9 mg/dl, an 1.0 
mg/dl increase in serum creatinine if the baseline serum 
creatinine was 2.0 to 4.9 mg/dl, and a 1.5 mg/dl increase in 
SCr if the baseline serum creatinine was 5.0 mg/dl [9]. Age 
and sex were recorded, and weight was measured soon after 
admission. Blood samples for determination of SCr, haemo-
globin and total protein, were drawn after overnight fasting 
at the time of admission. SCr assays were performed using 
the Jaffé method on a Hitachi Modular (Roche Diagnostics, 
Mannheim, Germany). Mean systolic and diastolic blood 
pressure (SBP and DBP) were calculated from the mean of 3 
values recorded at the time of admission. The treatment 
given during the admission, including dialysis sessions, was 
recorded. 
  Patients were classified into different types of CRS [1]. 
Type 1 was defined as acute cardiac decompensation leading 
to kidney injury, type 2 as CHF leading to worsening renal 
function, type 3 as acute kidney injury leading to cardiac 
dysfunction, type 4 as chronic kidney disease (CKD) leading 
to CHF, and type 5 as systemic conditions leading to both 
cardiac and renal dysfunction. Patients who died during   
admission and those with advanced cancer were excluded. 
Statistical Analysis 
  Data were expressed as mean ± SD or as percentage. 
Two-way  ANOVA was used to compare parametric con-
tinuous variables, while the Kruskal-Wallis test was used to 
compare nonparametric continuous variables. The Chi-
square test was used for estimating the occurrence of cate-
gorical variables. All p values were two-tailed, with statisti-
cal significance defined as p <0.05. Statview for Windows 
(version 3.0, SAS Institute Inc. San Francisco, CA) was used 
for the calculations. 
RESULTS 
  Out of 2,998 patients who were discharged form our unit 
in the study period, 438 (14.6%) were diagnosed with CRS. 
The mean age of this sample population was 80 ± 8 years, 
with 222 male patients (50.6%), 321 (73.2%) smokers, 229 
(52.2%) diabetic patients, 207 (47.2%) with clinical history 
of acute myocardial infarction (MI), 167 (38.1%) with chest 
Table 1.  Demographic, Anthropometric and Biochemical Data of the 5 types of Cardiorenal Syndrome  
 Type  1 
n = 211 (48.2%) 
Type 2 
n = 96 (21.9%) 
Type 3 
n = 88 (20.1%) 
Type 4 
n = 29 (6.6%) 
Type 5 
n = 14 (3.2%) 
p 
Age (years)  79.9 ± 8.4  78.5 ± 10.3  79.9 ± 7.6  79.5 ± 9.1  82 ± 7.4  ns 
Sex  (M/F)  111/101  54/41 45/43 8/21  4/10 0.032 
Weight (Kg)  73.3 ± 16.6  72.9 ± 11.4  70.4 ± 12.3  71.2 ± 12.3  73.9 ± 25.4  ns 
Hb (g/dl)  11.1 ± 2.0  11.8 ± 1.7  11.2 ± 2.2  10.9 ± 2.3  11.3 ± 1.4  ns 
Total protein (g/dl)  6.6 ± 0.8  6.7 ± 0.7  6.5 ± 0.8  6.6 ± 0.7  6.3 ± 0.5  ns 
Systolic BP (mmHg)  135.5 ± 25.5  138 ± 22.4  132.4 ± 24.5  147.9 ± 23.9
  117.1 ± 28 0.0017 
Diastolic BP (mmHg)  75 ± 12.9  75 ± 11.7  74.7 ± 13.2  73.2 ±10.9  69.2 ± 11.4  ns 
Admission duration (days)  9.9 ± 6.1  8.4 ± 5.7  10.4 ± 6.3  9.2 ± 6.7  16.7 ± 9.2  0.0017 
M = male. F = female, BP = blood pressure 
 4 vs 1 p = 0.0112 
 5 vs 1,2, 3, 4 p < 0.05 222    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Fabbian et al. 
pain, 135 (30.8%) with cerebrovascular disease and 339 
(77.3%) with PAD. The most frequent type of CRS was type 
1, and type 5 was the less frequent.  
  Demographic, anthropometric and biochemical data of 
the 5 types of CRS are listed in Table 1. Age was not signifi-
cantly different among the 5 CRS types; female sex and SBP 
were more prevalent in type 4 CRS. In contrast, SBP was 
lower in type 5 than in the other types. Hospital LOS was 
higher in type 5. Evaluation of renal function in the 5 types 
of CRS is shown in Table 2. SCr was lower and GFR was 
higher in type 2 than in the other types. The worst renal 
function was recorded in type 3 and 4. Results obtained from 
the eGFR equations were similar, although the MAYO equa-
tion tended to overestimate the value compared with the 
other formulae (Table 2). Smoking history was more preva-
lent in types 1, 2, 3, and IHD and chest pain were more   
frequent in types 1 and 2 than in the other types (Table 3). 
Diuretics and nitrates were given in a greater proportion of 
patients with type 1, dialysis treatment was performed in a 
few cases with type 3 and 4 (Table 4). 
DISCUSSION 
  Cardiorenal syndrome defines a condition due to com-
bined cardiac and renal dysfunction leading to the amplifica-
tion of the progression of failure of the individual organs and 
a bad prognosis. The aging of the population, the ameliora-
tion of cardiac invasive procedures leading to a better prog-
nosis of diseases that historically had a poor outcome have 
resulted in increasing number of patients with combined 
heart and kidney failure. Cardiorenal insufficiency is more 
than an association of cardiac and renal disease. Hyperten-
sion, widespread atherosclerotic vascular damage, and diabe-
tes mellitus are significant risk factors for both heart failure 
and renal failure. Patients with CRS appear to depend on the 
interaction of neurohumoral, hemodynamic, and other less 
known factors [10]. In patients with heart failure, renal dys-
function can result from intrinsic renal disease, hemody-
namic abnormalities, or their combination. Cardiac pump 
failure leads to low cardiac output and hypotension, respon-
sible of neurohormonal activation producing both fluid re-
tention and vasoconstriction. However, the cardiorenal rela-
tionship is more complex than the hemodynamic model 
alone; activation of the renin-angiotensin system, nitric ox-
ide, reactive oxygen species, inflammation, anemia and the 
sympathetic nervous system should also be taken into ac-
count [11]. 
  The association between CKD and CVD has been evalu-
ated in an unselected community based cohort of 2,471   
subjects aged 68 years [12]. Women with GFR 30-44 
ml/min/1.73m
2 and men with GFR 30-50 ml/min/1.73m
2 but 
without history of CVD had a hazard ratio for CVD of 1.51 
Table 2.  Renal Function in the 5 Types of Cardiorenal Syndrome  
 Type  1 
n = 211 (48.2%) 
Type 2 
n = 96 (21.9%) 
Type 3 
n = 88 (20.1%) 
Type 4 
n = 29 (6.6%) 
Type 5 
n = 14 (3.2%) 
p 
Creatinine (mg/dl)  2.05 ± 0.89
  1.71 ± 0.63  2.62 ± 1.26  2.58 ± 2.87  2.08 ± 0.48  <0.0001 
GFRMDRD186 (ml/min/1.73m
2)  34 ± 12
  41 ± 12
  27 ± 12  31 ± 12  28 ± 7  <0.0001 
GFRMDRD175 (ml/min/1.73m
2)  32 ± 12
  38 ± 12
  25 ± 11  29 ± 11  26 ± 7  <0.0001 
GFRCKD-EPI (ml/min/1.73m
2)  31 ± 12
  37 ± 12
  24 ± 11  28 ± 11  25 ± 7  <0.0001 
GFRMayo (ml/min/1.73m
2)  36 ± 16
  45 ± 16
  27 ± 14  33 ± 15  28 ± 10  <0.0001 
GFRC-G(ml/min)  32 ± 16
  37 ± 15
  25 ± 12  29 ± 14  24 ± 10  <0.0001 
GFR = glomerular filtration rate, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration, C-G = Cockcroft-Gault. 
 1 vs 2, 3 p < 0.0001 
 2 vs 3, 4, 5 p < 0.01 
 
Table 3.  Clinical Features of Patients with Respect of the 5 types of Cardiorenal Syndrome 
Clinical Features (%)  Type 1 
n = 211 (48.2%) 
Type 2 
n = 96 (21.9%) 
Type 3 
n = 88 (20.1%) 
Type 4 
n = 29 (6.6%) 
Type 5 
n = 14 (3.2%) 
p 
Smoking history  80  71  75  48  50  0.0016 
Diabetes history  50  53  56  48  57  ns 
Ischaemic heart disease  59  52  28  7  43  <0.0001 
Chest pain  50  40  19  3  43  <0.0001 
Cerebrovascular disease  27  30  42  27  3  ns 
Peripheral arterial disease  77  74  96  72  28  ns Clinical Features of Cardio-Renal Syndrome  The Open Cardiovascular Medicine Journal, 2011, Volume 5    223 
that increased to 2.39 in those with CVD history [12]. Wors-
ening of renal function is also an independent predictor of 
mortality in acute decompensated heart failure (ADHF) [13]. 
The prevalence of CRS is still a matter of debate. Between 
27 and 45% of subjects admitted for acute heart failure suf-
fered an acute worsening of renal function, with an increase in 
serum creatinine level (0.3 mg/dl) during hospitalization. [14]. 
 Heywood  et al. [15] reported that in 118,465 patients 
hospitalized for ADHF, 27.4% had mild renal dysfunction 
(GFR 60-89 ml/min/1.73m
2), 43.5% had moderate renal dys-
function (GFR 30-59 ml/min/1.73 m
2), 13.1% had severe 
renal dysfunction (GFR 15-29 ml/min/1.73m
2), and 7.0% 
had kidney failure (GFR <15 ml/min/1.73m
2 or chronic di-
alysis). Smith et al. published a systematic review of 16 
studies including 80,098 hospitalized and non-hospitalized 
CHF patients, and found that mortality increased by 7% for 
every 10 ml/min reduction in GFR evaluated at baseline 
[16]. Damman et al. [17] evaluated the relationship between 
worsening renal failure and mortality in 18,634 patients en-
rolled in 8 studies. Worsening renal failure was reported to 
develop in 25% of cases, and it was associated with a higher 
risk for mortality and hospitalization. In the present study, 
over a 30-month period, we identified 438 CRS cases out of 
2,998 patients discharged form our unit (prevalence = 14.6 
% and incidence = 14.6 patients/month).  
  Diagnosis of CRS is difficult, since physicians have to 
consider different interfering factors such as intravascular 
volume, use of non-steroidal anti-inflammatory drugs 
(NSAIDs), and drugs acting on the renin angiotensin aldos-
terone system (RAAS). Distinction between impaired renal 
function due to heart failure and underlying kidney disease is 
very important, since it allows classification of patients in 
the different types of CRS. In order to correctly classify our 
population we analyzed the records to detect urine sedi-
ments, with haematuria, casts or proteinuria and/or small 
kidneys on ultrasonography, features that suggest underlying 
renal disease. 
  Although the frequency of IHD in CKD patients is high, 
the use of cardioprotective drugs in this population is low. A 
study [18] of more than 3,000 dialysis patients with a 2-year 
follow-up, calculated an incidence of acute coronary syn-
dromes of 29/1,000 person-years. Nevertheless, cardiopro-
tective drugs were used in less than 50% of patients with 
known IHD, but they were not associated with significant 
benefit. A similar result was reported in 902 dialysis patients 
aged 65 years, admitted with MI. The authors concluded 
that elderly dialysis patients had excessively high mortality, 
and low use of standard cardioprotective therapies, such as 
angiotensin converting enzyme-inhibitors (ACEi) and/or 
angiotensin receptors blockers (ARBs), statins and beta-
blockers, but it remains uncertain whether this could be at-
tributable to a low use of cardiovascular medications. On the 
other hand, only ACEi use was associated with reduced risk 
of death [19]. Again, Berger et al. [20] found that aspirin, 
beta-blockers and ACEi were less likely to be administered 
to dialysis patients than the non-uremic ones. However, ana-
Table 4.  Pharmacological Treatment of Patients with Respect of the 5 Types of Cardiorenal Syndrome 
Pharmacological Treatment (%)  Type 1 
n = 211 (48.2%) 
Type 2 
n = 96 (21.9%) 
Type 3 
n = 88 (20.1%) 
Type 4 
n = 29 (6.6%) 
Type 5 
n = 14 (3.2%) 
p 
Loop diuretics  96  68  61  51  71  <0.0001 
Calcium channel blockers  33  39  52  62  21  0.002 
ACEi 43  50  27  45  35  0.0297 
ARBs 11  16  11  7  2  ns 
Clonidine 6  6  8  14  1  ns 
Alpha-blockers 6  5  6  7  0  ns 
Beta-blockers 45  45  42  26  33  ns 
Statin 30  32  21  14  21  ns 
Nitrates 47  24  25  10  14  <0.0001 
Digoxin 12  6  5  3  1  ns 
Haemodialysis 0  0  4  3  0  0.0124 
Oral antidiabetic drugs  13  20  15  14  0  ns 
Insulin 25  20  24  27  57  ns 
Antiplatelets  drugs 80 82  88  93  78 ns 
Anticoagulants 17  10  9  7  2  ns 
ACEi = angiotensin converting enzyme-inhibitors; ARBs = angiotensin receptors blockers. 224    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Fabbian et al. 
lyzing 145,740 non-uremic patients and 1,025 dialysis sub-
jects admitted for MI, the benefit of these therapies on 30-
day mortality was similar in the 2 groups [20]. Treatment for 
ADHF is frequently complicated by worsening renal func-
tion, drawing the picture of type 1 CRS. Results from the 
Evaluation Study of Congestive Heart Failure and Pulmo-
nary Artery Catheterization Effectiveness trial showed that, 
in the group of patients with hemoconcentration, the dose of 
loop diuretics was higher, renal function was worse, and 
180-day mortality was lower compared with the group with-
out hemoconcentration [21]. Felker et al. [22] conducted a 
prospective, double blind, randomized trial in 308 subjects 
with ADHF treated with intravenous furosemide. Patients 
were randomly assigned to receive low-dose of loop diuretic, 
equal to their daily oral dose or high-dose, equal to 2.5 times 
their total oral dose, and to furosemide either by intravenous 
bolus every 12 h or by continuous intravenous infusion. The 
mean change in the SCr 72 h after starting furosemide ther-
apy was similar comparing bolus vs continuous and low-
dose vs high-dose, and the mean values of SCr increase was 
between 0.04 and 0.08 mg/dl [22]. 
  Inhibition of the RAAS with ACEi or ARBs is a well 
established treatment for CHF, being associated with symp-
tomatic improvement, reduced hospitalization and increased 
survival. We should take into consideration that CRS could 
represent an effect of physician intervention, since ACEi and 
ARBs could decrease renal function, increasing SCr values, 
even if they improve outcome [23]. A different therapeutic 
approach could influence renal function as well, since it has 
been shown that resynchronization therapy can ameliorate 
renal function in subjects with GFR lower than 30 
ml/min/1.73m
2 [24]. Blasco et al. [25] evaluated 751 patients 
with acute MI admitted to a coronary care unit (CCU). Sub-
jects with GFR lower than 60 ml/min/1.73m
2 were older, had 
greater comorbidities, congestive heart failure and higher 
mortality than those with GFR equal or greater than 60 
ml/min/1.73m
2. Renal impairment was an independent pre-
dictor of mortality during CCU stay. On the other hand, 
among patients with diabetes and CVD, the presence of CHF 
acts as a trigger for detecting CKD [26]. 
  Our study showed that diuretics were taken by 96% of 
type 1 CRS patients and ACEi were taken by nearly half of 
subjects with CRS type 1, 2 and 3, and nearly one third   
of those with CRS type 3 and 4. In contrast, ARBs were   
recorded in lower percentages of patients. 
 Carnevale  et al. [27] reported that Mayo Clinic Quadratic 
equation could overestimate true renal function in older   
adult patients, since GFRMAYO had a mean value of 158 
ml/min/1.73m
2, nearly 100 ml/min/1.73m
2 higher, compared 
with creatinine clearance evaluated with 24-h urine collec-
tion that was measured to be 56.6 ml/min/1.73m
2. Our   
results are in agreement with these results since GFRMayo 
recorded the highest values in different subtypes of CRS. 
  Our study has limitations. First, the optimal evaluation of 
renal function would require subjects in a stable condition. In 
our study, we evaluated patients according to the criteria by 
Hou et al. [9] and calculated GFR in order to compare all 
different CRS subtypes. Second, we did not consider that 
patients could move across different CRS subtypes during 
the course of the disease. Moreover, we did not systemati-
cally check for laboratory biomarkers, but only when the 
physician, on admission, needed to improve diagnostic   
accuracy. Third, we do not report detailed functional and 
structural cardiac assessment by echocardiography. How-
ever, our aim was merely to clinically characterize the 5 
types of CRS, thus helping physicians to deal with elderly 
co-morbid patients and recognize CRS in everyday clinical 
practice. On the other hand it should be underlined that the 
number of patients in the different types of CRS is low   
especially in type 4 and 5, and we cannot exclude inaccuracies 
in definitions. Finally, our study has all the disadvantages of 
a retrospective design.  
  To the best of our knowledge, this is the first study that 
made an attempt to diagnose CRS in a large sample of   
patients consecutively discharged from an Internal Medicine 
ward. This represents the “real life world” of general hospital 
patients. As suggested by others [28], we also believe   
that prevention of CRS may play a key role although the 
treatment targets may not be well defined.  
  The management of intravascular volume, blood pressure 
and cardiac output, renal haemodynamic, anaemia, and in-
trinsic renal disease are essential and in order to preserve the 
equilibrium of each individual patient often necessitating a 
multidisciplinary approach.  The overall goals of manage-
ment of these patients should be to normalize volume status 
while avoiding overdiuresis and to control renal dysfunction, 
and to implement pharmacological and device therapy to 
improve patient outcomes [29]. Drugs that are commonly 
prescribed in heart failure, such ACEi, beta-blockers, and 
spironolactone, are rather underused in CRS although it has 
been suggested that these drugs could be useful in CKD [30]. 
On the other hand patients with heart and renal failure have 
been underrepresented in trials. Therefore little evidence is 
available to guide physicians in the optimal management of 
patients with both conditions [31]. 
  Physicians should pay attention in recognizing the coex-
istence of heart and renal failure, and GFR should be always 
calculated in order to detect CKD. In fact, early recognition 
of CRS could allow careful follow-up and strategies of man-
agement of these high risk patients. 
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